<DOC>
	<DOCNO>NCT01104298</DOCNO>
	<brief_summary>The propose investigation intend explore combination trabectedin doxorubicin first line treatment advance sarcoma obtains well result doxorubicin monotherapy</brief_summary>
	<brief_title>Doxorubicin vs. Trabectedin Plus Doxorubicin Non Operable and/or Metastatic STS</brief_title>
	<detailed_description>The propose investigation intend explore combination trabectedin doxorubicin first line treatment advance sarcoma obtains well result doxorubicin monotherapy . This proposal arise need bring first line treatment advance STS agent show activity second line . The goal improve available standard treatment . Tumors patient previously expose chemotherapy select biological behavior best scenario test antitumor activity new anticancer drug . The combination drug different mechanism action may clear advantage obtain good result potential synergy . On hand , toxicity profile study drug different worsen summative adverse effect expect . The purpose study determine efficacy combination trabectedin doxorubicin comparison doxorubicin alone patient advance non operable and/or metastatic Soft Tissue Sarcomas ( STS ) .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<criteria>The patient must sign voluntarily inform consent study test conduct part routine patient care , knowledge he/she abandon study time without affect his/her previous care . Aged 18 70 . Pathological diagnosis non operable and/or metastatic soft tissue sarcoma . The following histological subtypes include : Undifferentiated pleomorphic sarcoma ( previously , malignant fibrous istiocytoma ) Leiomyosarcoma Angiosarcoma Liposarcoma Synovial sarcoma Fibrosarcoma Hemangiopericytoma Neurofibrosarcoma Mixofibrosarcoma Unclassified sarcoma Measurable disease , accord RECIST criterion Performance status 02 Eastern Cooperative Oncology Group ( ECOG ) . Adequate bone marrow function ( hemoglobin &gt; 10 g/dL , leukocytes ≥ 3.000/mm3 , neutrophil ≥1.500/mm3 , platelet ≥ 100.000/mm3 ) . Patients plasma creatinine ≤ 1,6 mg/dL , transaminases ≤2.5 time upper limit normal ( ULN ) , total bilirubin ≤ upper limit normal ( ULN ) , CPK ≤ 2.5 time upper limit normal ( ULN ) , alkaline phosphatase ≤ 2.5 time upper limit normal ( ULN ) acceptable . If increase alkaline phosphatase &gt; 2.5 time upper limit normal ( ULN ) , alkaline phosphatase liver fraction and/or 5 ' nucleotidase and/or GGT must ≤ upper limit normal ( ULN ) . Men woman child bear potential use effective method contraception entry study throughout 6 month end study . Women childbearing potential must negative urine pregnancy test study entry . Normal cardiac function Left ventricular ejection fraction ( LVEF ) ≥ 50 % echocardiogram Multiple Uptake Gated Acquisition Scan ( MUGA ) . Previous chemotherapy treatment . Previous radiotherapy involve localization ( ) measurable tumoral disease . Performance status &gt; 2 Eastern Cooperative Oncology Group ( ECOG ) . Central Nervous System ( CNS ) metastases . Plasma bilirubin &gt; upper limit normal ( ULN ) . Creatinine &gt; 1.6 mg/dL . History neoplastic disease exception basalioma situ cervical cancer adequately treat . Significant cardiovascular disease ( example , dyspnea &gt; 2 NYHA ) Significant systemic disease grade 3 high NCICTC version 3.0 scale , limit patient availability , accord investigator judgment may contribute significantly treatment toxicity . Uncontrolled bacterial , mycotic viral infection . Women pregnant breastfeed Psychological , familial , social geographic circumstance limit patient 's ability comply protocol inform consent . Patients participate another clinical trial receive investigational product . Patients participate another clinical trial and/or receive investigational product last 30 day prior inclusion . The following histologic subtypes exclude : Rhabdomyosarcoma Ewing 's family tumor Desmoplastic small round cell tumor Clear cell sarcoma Alveolar sarcoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>metastatic STS</keyword>
	<keyword>Trabectedin</keyword>
	<keyword>doxorrubicin</keyword>
	<keyword>soft tissue sarcoma</keyword>
	<keyword>non operable sarcoma</keyword>
</DOC>